At the time of writing, Cardiff Oncology Inc [CRDF] stock is trading at $2.0, down -1.96%. An important factor to consider is whether the stock is rising or falling in short-term value. The CRDF shares have lost -10.71% over the last week, with a monthly amount drifted -10.31%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cardiff Oncology Inc [NASDAQ: CRDF] stock has seen the most recent analyst activity on July 08, 2025, when Ladenburg Thalmann initiated its Buy rating and assigned the stock a price target of $19. Previously, Jefferies started tracking the stock with Hold rating on June 24, 2025, and set its price target to $3.50. On September 06, 2024, Craig Hallum initiated with a Buy rating and assigned a price target of $8 on the stock. William Blair started tracking the stock assigning a Outperform rating. Robert W. Baird initiated its recommendation with a Outperform and recommended $19 as its price target on December 08, 2021. In a note dated October 22, 2020, H.C. Wainwright initiated a Buy rating and provided a target price of $27 on this stock.
For the past year, the stock price of Cardiff Oncology Inc fluctuated between $1.90 and $5.64. Cardiff Oncology Inc [NASDAQ: CRDF] shares were valued at $2.0 at the most recent close of the market.
Analyzing the CRDF fundamentals
According to Cardiff Oncology Inc [NASDAQ:CRDF], the company’s sales were 0.50M for trailing twelve months, which represents an -27.27% plunge. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -140.96%, Pretax Profit Margin comes in at -132.37%, and Net Profit Margin reading is -132.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.79, Equity is -0.77 and Total Capital is -1.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.95 points at the first support level, and at 1.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.05, and for the 2nd resistance point, it is at 2.10.
Ratios To Look Out For
It is important to note that Cardiff Oncology Inc [NASDAQ:CRDF] has a current ratio of 4.20. On the other hand, the Quick Ratio is 4.20, and the Cash Ratio is 0.69. Considering the valuation of this stock, the price to sales ratio is 269.45, the price to book ratio is 2.75.
Transactions by insiders
Recent insider trading involved PACE GARY W, Director, that happened on Jul 30 ’25 when 0.28 million shares were purchased. Director, PACE GARY W completed a deal on Jul 30 ’25 to buy 15000.0 shares. Meanwhile, Chief Financial Officer Levine James E. bought 2752.0 shares on Dec 17 ’24.
